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Non steroidal anti- inflammatory drugs have their origin 
as the derivatives of plants, which were observed to have their 
therapeutic effects in different disease states. They have the 
advantage of local action without developing central adverse 
effects and cognitive impairments. Side effects have been well 
described, although partly neglected. Topical delivery of NSAID 
has its therapeutic applications in management of pain and 
inflammation in rheumatoid arthritis patients. Rheumatoid 
arthritis is a chronic systemic inflammatory disorder that may 
affect many tissues and organs but principally attacks the 
synovial joints. It can be disabling and painful condition, which 
can lead to substantial loss of functioning and mobility if not 
adequately treated. The aim of the present investigation was 
to compare the ketoprofen cream with diclofenac and 
piroxicam cream in a group of volunteers suffered from 
rheumatoid arthritis and to compare the efficacy of these 
creams in reduction of inflammation. This single blind 
comparative study was done to determine the efficacy, 
tolerability and acceptability of topical application of ketoprofen 
cream (1%w/w) vs diclofenac cream (1%w/w) and piroxicam 
cream (0.5%w/w) in rheumatoid arthritis patients. In this 
study, one hundred and twenty five volunteers suffering with 
acute rheumatoid arthritis and age group between 40-70 years 
were analyzed for assessing the intensity of pain and anti-
inflammatory effects of these three creams. The study 
revealed that ketoprofen cream provides a good level of pain 
relief removes swelling and tenderness and improves the 
functional impairment, without the systemic adverse events 
associated with oral NSAIDs. 
 




Rheumatoid arthritis is an autoimmune 
progressive disorder that leads to the 
destruction of cartridge, bone and ligaments 
causing deformity of joints (Wolfe and Hawley 
1998). The cause of rheumatoid arthritis is 
unknown. It is believed that the tendency to 
develop rheumatoid arthritis may be genetically 
inherited (hereditary). Certain genes have been 
identified that increase the risk for rheumatoid 
arthritis (Pedersen et al., 2007). Non-steroidal 
anti-inflammatory drugs (NSAIDs) are widely 
used to relieve pain and inflammation in 
rheumatoid arthritis patients, but their use 
comes at the cost of toxicity, with a 2-4% 
annual incidence of serious gastrointestinal 
ulcer and complications—four times higher 
than in non-users (Lanas, 2009). NSAIDs have 
been applied topically for decades. This route 
possibly reduces gastrointestinal adverse 
reactions by maximizing local delivery and 
minimizing systemic toxicity (Massó González 
et al., 2010). Ketoprofen, diclofenac and 
piroxicam are the drugs included in the class of 
non-steroidal anti-inflammatory drugs 
(NSAIDs), each drug has a specific tissue 
distribution and pharmacodynamics (Rainsford 
et al., 2008). They block the inflammatory 
cascade and cycloxygenases (COX) by 
inhibiting prostaglandin and thromboxane 
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production and lead to reduction in pain,  
fever, platelet aggregation and inflammatory 
response (Rao, 2008). Besides inhibiting the 
prostaglandin and thromboxane production, 
Ketoprofen also inhibit rabbit neutrophil        
and human lung lipoxygenase activity (Kokki 
2002). NSAIDs like ketoprofen, diclofenac       
and piroxicam are generally indicated for 
symptomatic relief of rheumatoid arthritis, 
osteoarthritis (Towheed 2006), inflammatory 
arthropathies (Ankylosing spondylitis, psoriatic 
arthritis), gout (Massey et al., 2010), metastatic 
bone pain, post operative pain, dysmenorrhoea 
(Brunton, et al.,2006), migraine and headache. 
The use of oral preparations of NSAIDs 
increase the risk of gastrointestinal and 
cardiovascular complications compared with 
non NSAIDs users (Aronson, 2005). Reduction 
of adverse drug reactions associated with the 
use of topical preparations of NSAIDs is being 
well considered to obtain high patient 
compliance and drug therapy efficacy (Bjorkman,  
1999). Substantial data suggests that topical 
NSAIDs have pain-relieving properties in 
rheumatoid arthritis disease. An important           
sign of the increasing importance of using 
topical medication is that the European          
League against Rheumatism and the 
International Osteoarthritis Research Society 
state that topical NSAIDs are preferred over oral 
NSAIDs for mild-to-moderate hand and knee 
osteoarthritis, in patients with sensitivity to oral 
compounds (Altman and Barkin, 2009). In 
addition, the UK NICE guidelines for knee and 
hand osteoarthritis recommend use of 
paracetamol and/or topical NSAIDs over oral 
NSAIDs, COX2 inhibitors, and opioids 
(Conaghan, et al.,  2008). 
 
MATERIAL AND METHODS 
Human volunteers: 125; Gender: Male 
and Female; Age: 40-70 years; Cream 
Formulations: Ketoprofen cream (1% w/w) 
(Nazir et al., 2013); Diclofenac cream (1% 
w/w); Pioxicam cream (0.5% w/w) 
 
Methods 
This is a single blind, randomized 
comparative trial conducted at three different 
locations: Bajwa Trauma Centre, Sargodha, 
Pakistan; Amin Orthopedic Centre, Sargodha, 
Pakistan; National Hospital, Faisalabad, 
Pakistan. One hundred  and twenty  five  
volunteers  were  divided into three groups 
receiving ketoprofen cream, diclofenac cream 
and/or piroxicam cream. The  volunteers were 
given  written  instructions to  apply  the  cream  
regularly on affected area in  a  dose  of 4  
inches 3-4  times a day  up to 14 days. 
Volunteers both (males and non- pregnant 
females) between the ages of 40-70 suffered 
from acute rheumatoid arthritis were included 
in this study. 
 
Inclusion criteria for study 
The volunteer is 40-70 years of age; The 
volunteer is diagnosed with uncomplicated 
acute rheumatoid arthritis; The site of injury is  
accessible to  the  volunteer so  that  he/she  
can apply the study medication  himself/herself; 
The volunteer must meet the pain entry criteria; 
The volunteer is willing to discontinue use of 
any pain medication not provided as a part of 
study 
 
Exclusion criteria for study 
The volunteer has active skin lesions at 
the intended site of   application of study 
medication. Skin  lesions  include  open wound,  
rash,  papules,  vesicles and  erythema 
associated with the site of injury. The volunteer 
has used any form of opoids since the time of 
injury. The volunteer has taken any form of 
steroids within 30 days prior to enter into 
study. The volunteer has done non- 
pharmacological treatment of injury. The  
volunteer has   experienced  any  kind  of  
allergy to ketoprofen, diclofenac or piroxicam. 
The volunteer has participated in an 
investigational drug study or received an 
investigational drug within a period of 30 days 
prior receiving the study mediation. Recent 
injuries sustained within 4h (not requiring 
surgical treatment) were included under "acute" 
category. Written informed consent was 
obtained prior to enrollment of patients in the 
study. The patients were evaluated before 
initiation of therapy and then at day 1, day 4, 
day 8 and day 14 of the therapy for the 
following parameters. 
Pain intensity on a 10cm visual analogue 
scale (0-worst ever, 10-best ever); pain at rest, 
passive movement, palpation and isometric 
contraction on a 4 point scale (0-absent, 1-mild, 
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2-moderate, 3-severe); Tenderness on a 4 point 
scale (0-not tender, 1-tender, 2-winced, 3-
withdrew); Swelling on a 4 point scale (0-
absent, 1-mild, 2-moderate, 3-severe); 
Functional impairment on 5 point scale: (o-
none, 1 mild, 2 moderate, 3 marked and 4 
severe); Paracetamol was given as rescue drug 
in case the pain relief by topical formulations 
was inadequate. The amount of paracetamol 
intake was recorded as indirect measurement of 
effectiveness of the trail drugs. 
 
RESULTS AND DISCUSSION 
A total of 125 patients of aged between 
40-70 years were enrolled in this study. 
However 15 patients were lost to follow up and 
only 110 patients were evaluated. A total of 45 
patients received ketoprofen cream, 35 received 
diclofenac cream and 30 received piroxicam 
cream. The ratio of males to females in the 
study was 19:25 (48/62). The patient’s 
demographics of all three groups were 
comparable (Table I). 
Within the group all the three groups 
had improvement in the various parameters 
studied (onset of pain; pain intensity on a 10cm  
VAS; pain at rest, passive movement; palpation 
and isometric contraction; swelling; tenderness: 
and functional impairment). This improvement 
was statistically significant when compared at 
the beginning and end of the therapy. 
However, over the study period of 14 days 
there was no significant change in the 
paracetamol intake in all the three groups. 
The onset of pain relief was observed 
between 1-2 hours. In some cases the onset of 
pain relief was quite delayed but there was not 
much difference between groups. The between 
group analysis showed that treatment with 
ketoprofen cream was significantly more 
effective than diclofenac cream and clinically 
better than piroxicam cream. The pain intensity 
on 10cm visual analogue scale was best          
ever 98% with ketoprofen cream group, 80% 
with diclofenac cream and 84% with  piroxicam   
cream   group at the end of therapy.  
Table I. Patient demographics. 
 
Parameters Ketoprofen cream  Diclofenac cream Piroxicam cream 
Total no. of patients 45 35  30 
Sex: 
Male 22              15 11 
Female 23 20 19 
 
 





(n = 45) 
Diclofenac cream 
(n = 35) 
Piroxicam cream        
(n = 30) 
 1 4 8 14 1 4 8 14 1 4 8 14 
Pain intensity on 
VAS (cm) 
4.15 6.29 7.55 9.77 3.75 4.88 6.29 8.01 3.99 5.01 7.0 8.44 
Pain at rest 2.1 1.8 0.7 0.1 2.1 1.9 1.2 0.9 2.1 1.8 1.2 0.8 
Pain on passive 
Motion 
2.3 1.9 0.9 0.2 2.3 2.0 1.4 0.9 2.3 1.9 1.3 0.8 
Pain on palpation 2.7 2.1 1.2 0.5 2.7 2.2 1.7 1.0 2.7 2.1 1.6 0.9 
Pain on isometric 
Contraction 
3.0 2.4 1.5 0.6 3.0 2.6 1.9 1.2 3.0 2.5 1.6 1.0 
Tenderness 2.5 1.8 0.9 0.2 2.5 2.0 1.3 0.8 2.5 1.9 1.1 0.6 
Swelling 3.0 2.1 1.4 0.3 3.0 2.4 1.8 1.0 3.0 2.2 1.5 0.8 
Functional 
Impairment 
3.5 2.6 1.6 0.5 3.5 2.9 2.0 1.1 3.5 2.8 1.9 0.9 
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The pain intensity mean score of 9.77cm (when 
assessed on 0-10 cm VAS) for ketoprofen 
cream was statistically more significant 
(p<0.01) than diclofenac and piroxicam cream 
whose mean scores were 8.01and 8.44 
respectively indicated by number 1 on x-axis in 
figure 1. 
At day 14, 98% improvement was seen 
in patients with pain at rest with ketoprofen 
cream, 82% with diclofenac cream and 84% 
with piroxicam cream. pain at passive motion 
was improved up to 96% with ketoprofen 
cream than 82% and 84% with diclofenac and 
piroxicam groups respectively. Pain at 
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palpitation and isometric contraction was 
improved upto 90% and 88% with ketoprofen 
cream group respectively, 80% and 78% with 
diclofenac cream group respectively and 82% 
and 80% with piroxicam cream respectively as 
shown by number 2, 3, 4 and 5 on x-axis in 
figure I. 
Clinically tenderness was absent up to 
96% in ketoprofen cream group, 92% in 
diclofenac cream group and 94% in piroxicam 
cream group representated by number1 on x-
axis in figure ii. Absence in swelling was 
observed 94% with ketoprofen cream group as 
compared to 80% and 84% with diclofenac and 
piroxicam group at the end of therapy. 
Functional improvement was seen 90% with 
ketoprofen cream group than 78% and 82% 
with diclofenac and piroxicam cream groups 
respectively as shown in figure II. 
No statistically significant difference was 




Ketoprofen, diclofenac and piroxicam all 
three are nsaids that exhibit analgesic, 
antipyretic and anti-inflammatory activities. 
From the above results it can be concluded that 
on day 14 ketoprofen cream was statistically 
better (p<0.01) in reducing pain, tenderness, 
and swelling and improves the functional ability 
than diclofenac cream. Piroxicam cream rated 
better (p<0.05) in these parameter as compared 
to diclofenac cream. 
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